Agenda Links: Day 1
AGENDA: DAY 2
WEDNESDAY, JUNE 28, 2017
7:30 am
Registration Commences/Networking Breakfast
MORNING PLENARY SESSION
8:00 am
Risk-Sharing Arrangements for Pharmaceuticals and Medical Devices: Anti-Trust and FDA Regulatory Issues
Vasiliki “Viki” Kalaitzidis, JD
Associate General Counsel, Managed Markets and Operations, EMD Serono, Rockland, MA
Associate General Counsel, Managed Markets and Operations, EMD Serono, Rockland, MA
Stephen Paul Mahinka, JD
Partner, Morgan, Lewis & Bockius LLP, Washington, DC
Partner, Morgan, Lewis & Bockius LLP, Washington, DC
8:45 am
Considerations for Hubs and Specialty Pharmacy Arrangements
Terra Buckley
Director, Compliance, Helsinn Therapeutics (U.S.), Inc.; Former Director, Ethics & Compliance, North America, Ipsen; Former Associate Director, Compliance, Aptalis Pharma/Forest Laboratories, Iselin, NJ
Director, Compliance, Helsinn Therapeutics (U.S.), Inc.; Former Director, Ethics & Compliance, North America, Ipsen; Former Associate Director, Compliance, Aptalis Pharma/Forest Laboratories, Iselin, NJ
Seth H. Lundy, JD
Partner, King & Spalding, Washington, DC
Partner, King & Spalding, Washington, DC
9:30 am
Enforcement Trends, Risk Assessments, and Best Practices in Compliance Controls for Patient Services Programs
Eliza L. Andonova, JD
Counsel, Hogan Lovells, Washington, DC
Counsel, Hogan Lovells, Washington, DC
Jennifer Chillas, JD
Senior Corporate Counsel, Bristol-Myers Squibb, Princeton Pike, NJ
Senior Corporate Counsel, Bristol-Myers Squibb, Princeton Pike, NJ
Laura Hoey, JD
Partner, Ropes & Gray , Chicago, IL
Partner, Ropes & Gray , Chicago, IL
Casey Horton
Director, Healthcare and Life Sciences Disputes, Regulatory, Compliance and Investigations, Navigant; Former Director, Compliance Operations, AbbVie, Chicago, IL (Moderator)
Director, Healthcare and Life Sciences Disputes, Regulatory, Compliance and Investigations, Navigant; Former Director, Compliance Operations, AbbVie, Chicago, IL (Moderator)
10:15 am
Break
10:45 am
Considerations for Value-Based Contracting
Thomas W. Beimers, JD
Partner, Hogan Lovells; Former Senior Counsel for Administrative and Civil Remedies, Office of the Inspector General, Department of Health and Human Services, Minneapolis, MN
Partner, Hogan Lovells; Former Senior Counsel for Administrative and Civil Remedies, Office of the Inspector General, Department of Health and Human Services, Minneapolis, MN
John S. Linehan, JD
Healthcare Attorney, Epstein Becker Green; Former Special Assistant US Attorney , US Attorney’s Office for the District of Maryland, Washington, DC
Healthcare Attorney, Epstein Becker Green; Former Special Assistant US Attorney , US Attorney’s Office for the District of Maryland, Washington, DC
11:30 am
Current Perspectives: Challenges to the PBM Environment
Meenakshi Datta, JD
Partner, Sidley Austin LLP, Chicago, IL
Partner, Sidley Austin LLP, Chicago, IL
12:15 pm
Luncheon
AFTERNOON CLOSING PLENARY SESSION
1:15 pm
Collaboration to Advance Value Frameworks
Edmund Pezalla, MD, PhD
Chief Executive Officer, Enlightenment Bioconsulting; Former Vice President, National Medical Director, Pharmaceutical Policy and Strategy, Aetna, Hartford, CT
Chief Executive Officer, Enlightenment Bioconsulting; Former Vice President, National Medical Director, Pharmaceutical Policy and Strategy, Aetna, Hartford, CT
2:00 pm
Pricing Transparency and New Proposed Models for Pharmaceutical Pricing
Susan Asante-Abedi, MS
Senior Principal, QuintilesIMS, New York, NY
Senior Principal, QuintilesIMS, New York, NY
2:40 pm
Implications of the Evolving Landscape on Government Price Reporting
Chris Cobourn, MA
Managing Director, Huron Consulting Group, Philadelphia, PA
Managing Director, Huron Consulting Group, Philadelphia, PA
John D. Shakow, JD
Partner, FDA and Life Sciences Practice, King & Spalding; Vice Chair, ABA Health Care Contracting Committee, Washington, DC
Partner, FDA and Life Sciences Practice, King & Spalding; Vice Chair, ABA Health Care Contracting Committee, Washington, DC
3:10 pm
Break
3:40 pm
Compliance Program Considerations Applicable to the Managed Markets Business
Blake Bolinger, JD
Director, US Pharmaceuticals, Compliance and Ethics, Bristol-Myers Squibb, Princeton Pike, NJ
Director, US Pharmaceuticals, Compliance and Ethics, Bristol-Myers Squibb, Princeton Pike, NJ
Carla Brooks, MS
Director, Compliance, Market Access and Government Affairs, AstraZeneca, Gaithersburg, MD
Director, Compliance, Market Access and Government Affairs, AstraZeneca, Gaithersburg, MD
Thomas Kidd
Advisor, Ethics and Compliance, Eli Lilly and Company, Indianapolis, IN
Advisor, Ethics and Compliance, Eli Lilly and Company, Indianapolis, IN
Mark DeWyngaert, MBA, PhD
Managing Director, Huron Life Sciences, New York, NY (Moderator)
Managing Director, Huron Life Sciences, New York, NY (Moderator)
4:30 pm
Adjournment
Agenda Links: Day 1